(Total Views: 566)
Posted On: 10/01/2020 5:45:53 PM
Post# of 154416
Quote:
The big question is -- if Vyera pricing precludes piecemeal partnering and licensing of individual indications, then what exactly are they talking about with those 11 Big Pharma companies?
Either a buyout or a distribution deal for all other indications excluding HIV and COVID-19 (for the next 3 years). That we are looking at overseas distribution deals I think it's more likely U.S. distribution.
(1)
(0)
